UCL 2077

• Description :

  UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization[1]. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels[2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ucl-2077.html

• Purity :

  98.91

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  C1(CNC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC=CN=C1

• Molecular Formula :

  C25H22N2

• Molecular Weight :

  350.46

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Shah MM, et al. Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3- (triphenylmethylaminomethyl) pyridine (UCL2077) . Mol Pharmacol. 2006 Nov;70 (5) :1494-502.|[2]Soh H, et al. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol Pharmacol. 2010 Dec;78 (6) :1088-95.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [918311-87-2]